McKesson acquires 80% ownership in PRISM Vision Holdings, diversifying its business into the high-growth area of ophthalmology. The deal is to be accretive this year.
MCK IS UP OVER 14 POINTS AFTER THE TRADEPULSE ALERT
An aging U.S. population is increasing the demand for medication, and this company delivers.
In the most recent trading session, McKesson (MCK) closed at $672.99, indicating a +0.74% shift from the previous trading day.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily.
McKesson (MCK) closed at $660.86 in the latest trading session, marking a -0.05% move from the prior day.
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Investing in dividend growth stocks is a smart, reliable way to build passive income that lasts a lifetime, and it's worth considering if you're eyeing financial freedom.
In the latest trading session, McKesson (MCK) closed at $663.79, marking a +0.33% move from the previous day.
McKesson (MCK) closed at $643.69 in the latest trading session, marking a +0.47% move from the prior day.
As of early March 2025, investors—and consumers—have once again begun to feel skittish about the possibility of an impending recession. At least two major factors have contributed most recently to this sentiment: first, a dreaded inverted yield curve in the final days of February, and second, the Atlanta Fed's model to predict GDP growth for the first quarter of the year was revised down to -2.8% on March 3, when it had been +4.0% about a month before.